%0 Journal Article
%T Anti¨Cnerve growth factor therapy attenuates cutaneous hypersensitivity and musculoskeletal discomfort in mice with osteoporosis
%A Chisato Mori
%A Laura S. Stone
%A Magali Millecamps
%A Miyako Suzuki
%A Seiji Ohtori
%J Archive of "Pain Reports".
%D 2018
%R 10.1097/PR9.0000000000000652
%X The prevalence of osteoporosis is increasing with the aging population and is associated with increased risk of fracture and chronic pain. Osteoporosis is currently treated with bisphosphonate therapy to attenuate bone loss. We previously reported that improvement in bone mineral density is not sufficient to reduce osteoporosis-related pain in an ovariectomy (OVX)-induced mouse model of osteoporosis, highlighting the need for new treatments. Targeting of nerve growth factor (NGF) with sequestering antibodies is a promising new direction for the treatment of musculoskeletal pain including back pain and arthritis. Its efficacy is currently unknown for osteoporotic pain
%K Osteoporosis
%K Osteoporosis-related pain
%K Anti-NGF therapy
%K OVX-induced mouse model
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999413/